The UK Pharmacogenetics & Stratified Medicine Network (UKPGx) is a network for academics, clinicians and people from the industrial and regulatory sectors, which promotes the use of stratified/personalised medicine in the clinic, to offer patients the most appropriate and safe drug, at the optimal dose, at the start of their treatment. As of August 2023, the UKPGx Network is managed by the British Pharmacological Society.

​

Join the Network

 

Join the UKPGx Network for free. We invite everyone working or studying in fields related to pharmacogenetics and stratified medicine to get involved.

​

Definitions

 

Pharmacogenetics is research into how an individual’s genes affect their response to a particular medication. This research aims to improve drug development, efficiency and patient safety. 

​

Stratified medicine (otherwise known as 'personalised', 'precision', or 'P4' medicine) uses specialised diagnostic tests to groups patients according to their disease subtype to determine the most appropriate treatment.  It is also used  to predict risk of disease and then offer preventative treatment, or suggest changes in life style, to minimise the effect of disease.

​

Key Publications

Working together to deliver stratified medicine research effectively

Published 7 February 2019 by the British Medical Bulletin

(S.G. Attar†,S.G etal British Medical Bulletin, 2019, 1–10 doi: 10.1093/bmb/ldz003)

 

Stratified Medicine

Published by the Academy of Medical Sciences

 

Precision medicine and genomics

Updated 1 December 2021 by the Life Sciences Organisation and Department for International Trade

​

Genome UK: shared commitments for UK-wide implementation 2022 to 2025

Published 18 March 2022 by the Department for Science, Innovation and Technology, Department of Health and Social Care, Office for Life Sciences, Welsh Government, The Scottish Government, Department of Health (Northern Ireland), and Department for Business, Energy & Industrial Strategy

​